Allakos Completes Acquisition and Exits Public Markets
10.02.2026 - 19:11:04
The publicly traded chapter for Allakos Inc. has closed. The biotechnology firm has been fully acquired by Concentra Biosciences, integrated into the parent company, and delisted from the NASDAQ exchange. This move finalizes a volatile period for former shareholders, culminating in a cash payout.
- The acquisition by Concentra Biosciences has been finalized.
- Shareholders received a cash consideration of $0.33 per share.
- The company's stock has been removed from the NASDAQ.
- The focus now shifts to integrating Allakos's remaining drug development pipelines.
The decision to transition to a private entity was a direct consequence of significant operational challenges. In January 2025, Allakos disclosed disappointing clinical trial data for its lead development program, AK006, which was being investigated for the treatment of chronic spontaneous urticaria. Following this setback, the project was terminated. To preserve remaining capital, the company implemented substantial workforce reductions and initiated a strategic review. The merger with Concentra Biosciences emerged from this process as the chosen path to secure the company's assets.
An End to Public Market Catalysts
The completion of this transaction fundamentally alters the landscape for investors. Operating now as a private subsidiary, Allakos is no longer subject to public financial reporting requirements. Traditional stock price catalysts, such as quarterly earnings releases or the company's own announcements of clinical milestones, have ceased.
Should investors sell immediately? Or is it worth buying Allakos?
The fate of the former Allakos development programs rests entirely with Concentra Biosciences. Any future information regarding progress on these therapeutic approaches will be disseminated solely at the discretion of the parent company, outside of standard market communications channels.
With the integration of Allakos's assets into Concentra's portfolio complete, no further market-sensitive events or shareholder meetings are anticipated. The Allakos story on the public capital markets has concluded. All ongoing activities will be pursued within the broader strategic framework of Concentra Biosciences.
Ad
Allakos Stock: Buy or Sell?! New Allakos Analysis from February 10 delivers the answer:
The latest Allakos figures speak for themselves: Urgent action needed for Allakos investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 10.
Allakos: Buy or sell? Read more here...
